Convergent approaches for the synthesis of the antitumoral peptide, Kahalalide F. study of orthogonal protecting groups

Journal of Organic Chemistry

Volumn 71, Issue 19, 2006, Pages 7196-7204

  Gracia, Carolina ^a   Isidro Llobet, Albert ^a   Cruz, Luis J ^a   Acosta, Gerardo A ^a   Álvarez, Mercedes ^a   Cuevas, Carmen ^b   Giralt, Ernest ^a   Albericio, Fernando ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALGAE; BIODIVERSITY; COMPOSITION; REACTION KINETICS; SYNTHESIS (CHEMICAL);

ANALOGUES; ANTITUMORAL PEPTIDES; ELYSIA RUFESCENS; MARINE SPECIES;

ORGANIC COMPOUNDS;

ANTINEOPLASTIC AGENT; ENFUVIRTIDE; KAHALALIDE F; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRYOPSIS; CHEMICAL REACTION; DISSOLUTION; DRUG MANUFACTURE; DRUG SYNTHESIS; ELYSIA RUFESCENS; GEOMETRY; GREEN ALGA; MOLLUSC; SOLID;

ANIMALS; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; MOLLUSCA; PROTEIN CONFORMATION;

EID: 33749003452     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo060976f     Document Type: Article

References (44)

1. Hamann, M. T.; Scheuer, P. J. J. Am. Chem. Soc. 1993, 115, 5825-5826.
2. Hamann, M. T. Curr. Opin. Mol. Ther. 2004, 6, 657-665.
3. Janmaat, M. L.; Rodriguez, J. A.; Jimeno, J.; Kruyt, F. A. E. Mol. Pharmacol. 2005, 68, 502-510.
4. Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Muñoz, A. Mol. Cancer Ther. 2003, 2, 863-872.
5. Jimeno, J.; Faircloth, G.; Fernandez Souse-Faro, J. M.; Scheuer, P.; Rinehart, K. Mar. Drugs 2004, 2, 14-29.
6. Izquierdo Delso, M. A. PCT Int. Appl. (2004) WO 2004075910, A1 20040910, CAN 141:236712, AN 2004:740175.
7. Goetz, G.; Yoshida, W. Y.; Scheuer, P. J. Tetrahedron 1999, 55, 7739-7746 and 11957.
8. Lopez-Macia, A.; Jimenez, J. C.; Royo, M.; Giralt, E.; Albericio, F. J. Am. Chem. Soc. 2001, 123, 11398-11401.
9. Bonnard, I.; Manzanares, I.; Rinehart, K. L. J. Nat. Prod. 2003, 66, 1466-1470.
10. Albericio, F.; Fernandez, A.; Giralt, E.; Gracia, C.; Lopez, P.; Varon, S.; Cuevas, C.; Lopez-Macia, A.; Francesch, A.; Jimenez, J. C.; Royo, M. PCT Int. Appl. (2005) WO 2005023846, A1 20050317, CAN 142:298335, AN 2005:239012.
11. Lopez, P. E.; Isidro-Llobet, A.; Gracia, C.; Cruz, L. J.; Garcia-Granados, A.; Parra, A.; Alvarez, M.; Albericio, F. Tetrahedron Lett. 2005, 46, 7737-7741.
12. (a) Lloyd-Williams, P.; Albericio, F.; Giralt, E. Tetrahedron 1993, 49, 11065-11133.
13. (b) Lloyd-Williams, P.; Albericio, F.; Giralt, E. Chemical Approaches to the Synthesis of Peptides and Proteins; CRC Press: Boca Raton, FL, 1997.
14. Benz, H. Synthesis 1994, 4, 337-358.
15. (a) Barlos, K.; Gatos, D. Biopolymers 1999, 51, 266-278.
16. (b) Barlos, K.; Gatos, D. In Fmoc Solid-Phase Peptide Synthesis; Chan, W. C., White, P. D., Eds.; Oxford University Press: Oxford, UK, 2000; pp 215-228.
17. Sakakibara, S. Biopolymers 1999, 51, 279-296.
18. An orthogonal protecting scheme is defined as one based on completely different classes of protecting groups such that each class of groups can be removed in any order and in the presence of all other classes of protecting groups. Barany, G.; Albericio, F. J. Am. Chem. Soc. 1985, 107, 4936-4942.
19. Fields, G. B. Methods in Enzymology, Solid-Phase Peptide Synthesis; Academic Press: Orlando, Florida, 1997; Vol. 289.
20. Goodman, M.; Felix, A.; Moroder, L.; Toniolo, C. Houben-Weyl. Methods of Organic Chemistry. Synthesis of Peptides and Peptidomimetics; Georg Thieme Verlag: Stuttgart, Germany, 2001; Vol. E 22.
21. Bruckdorfer, T.; Marder, O.; Albericio, F. Curr. Pharm. Biotechnol. 2004, 5, 29-43.
22. Albericio, F. Curr. Opin. Chem. Biol. 2004, 8, 211-221.
23. Nisiuchi, Y.; Inui, T.; Nishio, H.; Bodi, J.; Kimura, T.; Tsuji, F. T.; Sakakibara, S. P Natl. Acad. Sci. U.S.A. 1998, 95, 13549-13554.
24. Chiva, C.; Barthe, P.; Codina, A.; Gain, M.; Molina, F.; Granier, C.; Pugniere, M.; Inui, T.; Nishio, H.; Nishiuchi, Y.; Kimura, T.i; Sakakibara, S.; Albericio, F.; Giralt, E. J. Am. Chem. Soc. 2003, 125, 1508-1517.
25. Bray, Brian L. Natl. Rev. Drug Discovery 2003, 2, 587-593.
26. (a) Barlos, K.; Gatos, D.; Schäfer, W. Angew. Chem., Int. Ed. Engl. 1991, 30, 590-593.
27. (b) Barlos, K.; Chatzi, O.; Gatos, D.; Stavropoulos G. Int. J. Pept. Protein Res. 1991, 37, 513-520.
28. Rovero, P.; Vigano, S.; Pegoraro, S.; Quartara, L. Lett. Pept. Sci. 1996, 2, 319-323.
29. Chiva, C.; Vilaseca, M.; Giralt, E.; Albericio, F. J. Pept. Sci. 1999, 5, 131-140.
30. If the loading is greater than 1 mmol/g, as most of the commercial available resins of this kind are, the analysis by HPLC-ESMS of the crude product shows additional peaks, corresponding to terminated sequences (see ref 26).
31. Garcia-Martin, F.; Bayo, N.; Cruz, L. J.; Tulla, J.; Bohling, J.; Albericio, F. Manuscript in preparation.
32. Isidro-Llobet, A.; Guasch-Camell, J.; Alvarez, M.; Albericio, F. Eur. J. Org. Chem. 2005, 3031-3039.
33. Isidro-Llobet, A.; Alvarez, M.; Albericio, F. Tetrahedron Lett. 2005, 46, 7733-7736.
34. The synthesis of peptides by convergent approaches and/or the cyclic peptides require the use of semi-permanent protecting groups, which must be stable to the conditions used to remove the temporal protecting group, which are those that are removed after each synthetic cycle and should be removed without affecting any permanent protecting groups, which removed in the final step of the synthetic process: Albericio, F. Biopolymers 2000, 55, 123-139.
35. Guibe, F. Tetrahedron 1997, 53 (40), 13509-13556;
36. Guibe, F. Tetrahedron 1998, 54, 2967-3042.
37. 1 is perfectly stable to the repetitive piperidine treatments during the stepwise elongation of the peptidic chain where the cycle is still not formed, the same ester bond is unstable to just one piperidine treatment once the cycle is already formed. This is a illustrative example of that the rigidity conferred by a cycle can change the physchem properties of a molecule.
38. Albericio, F.; Bofill, J. M.; El-Faham, A.; Kates, S. A. J. Org. Chem. 1998, 63, 9678-9683.
39. Carpino, L. A.; H-Faham, A.; Minor, C. A.; Albericio, F. J. Chem. Soc., Chem. Commun. 1994, 201-203.
40. These epimers did not show any remarkable biological activity in the typical cell lines used for evaluation the antitumorals activity of Kahalalide F and its analogues.
41. Dangles, O.; Guibe, F.; Balavoine, G.; Lavielle, S.; Marquet, A. J. Org. Chem. 1987, 52, 4984-4993.
42. Cruz, L. J.; Beteta, N. G.; Ewenson, A.; Albericio, F. Org. Process Res. Dev. 2004, 8, 920-924.
43. Albericio, F.; Giralt, E.; Jimenez, J. C.; Lopez, A.; Manzanares, I.; Rodrigues, I.; Royo, M. PCT Int. Appl. (2001) WO 2001058934, A2 20010816, CAN 135:167039, AN 2001:598019.
44. Spengler, J.; Jimenez, J. C.; Burger, K.; Giralt, E.; Albericio, F. J. Pept. Res. 2005, 65, 550-555.